{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:37:44Z","timestamp":1764304664997,"version":"3.41.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Inflammatory myofibroblastic tumors are rare soft tissue neoplasms with an uncertain biological behavior, derived from fibroblastic and myofibroblastic cells. In rare cases, a peculiar epithelioid phenotypic variant of this tumor is encountered, named epithelioid inflammatory myofibroblastic sarcoma (EIMS). EIMS has overlapping features with inflammatory myofibroblastic tumor but has been correlated with a more aggressive clinical course, a characteristic nuclear membrane or perinuclear anaplastic lymphoma kinase (ALK) immunostaining pattern and a very specific <jats:italic toggle=\"yes\">RANBP2<\/jats:italic>-<jats:italic toggle=\"yes\">ALK<\/jats:italic> fusion. To date, EIMS has been reported almost exclusively in the abdominal and pelvic cavity, with the exception of some intrathoracic cases. Herein, we present the first case of primary cutaneous EIMS, confirmed by molecular analysis showing the diagnostic <jats:italic toggle=\"yes\">RANBP2<\/jats:italic>-<jats:italic toggle=\"yes\">ALK<\/jats:italic> fusion.<\/jats:p>","DOI":"10.1097\/dad.0000000000002096","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T11:01:10Z","timestamp":1637751670000},"page":"302-305","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Primary Cutaneous Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring RANBP2-ALK Fusion: Report of an Exceptional Case"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-3166","authenticated-orcid":false,"given":"Laura","family":"Gadeyne","sequence":"first","affiliation":[{"name":"Dermpat, Ghent, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Creytens","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ghent University Hospital, Ghent, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Dekeyser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, General Hospital AZ Maria Middelares, Ghent, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joni","family":"Van der Meulen","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics Ghent University Hospital (MDG), Ghent University Hospital, Ghent, Belgium; and"},{"name":"CRIG, Cancer Research Institute Ghent, Ghent University, Ghent, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Haspeslagh","sequence":"additional","affiliation":[{"name":"Dermpat, Ghent, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jcp.2007.049387","article-title":"Inflammatory myofibroblastic tumours: where are we now?","volume":"61","author":"Gleason","year":"2008","journal-title":"J Clin Pathol."},{"key":"R2-20250616","first-page":"2776","article-title":"Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors","volume":"59","author":"Griffin","year":"1999","journal-title":"Cancer Res."},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/modpathol.3880352","article-title":"ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor","volume":"14","author":"Coffin","year":"2001","journal-title":"Mod Pathol."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0002-9440(10)64550-6","article-title":"TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors","volume":"157","author":"Lawrence","year":"2000","journal-title":"Am J Pathol."},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jcp.10472","article-title":"Anaplastic lymphoma kinase proteins in growth control and cancer","volume":"199","author":"Pulford","year":"2004","journal-title":"J Cell Physiol"},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/his.12910","article-title":"ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours","volume":"69","author":"Yamamoto","year":"2016","journal-title":"Histopathology"},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/his.12399","article-title":"Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH","volume":"65","author":"Hutarew","year":"2014","journal-title":"Histopathology"},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1097\/00000478-200111000-00003","article-title":"Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study","volume":"25","author":"Cook","year":"2001","journal-title":"Am J Surg Pathol."},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/gcc.10177","article-title":"Fusion of ALK to the ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor","volume":"37","author":"Ma","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.humpath.2008.04.016","article-title":"An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features","volume":"39","author":"Chen","year":"2008","journal-title":"Hum Pathol."},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/PAS.0b013e318200cfd5","article-title":"Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK","volume":"35","author":"Mari\u00f1o-Enr\u00edquez","year":"2011","journal-title":"Am J Surg Pathol."},{"key":"R12-20250616","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cancergencyto.2007.04.004","article-title":"RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors","volume":"176","author":"Patel","year":"2007","journal-title":"Cancer Genet Cytogenet."},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","article-title":"Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor","volume":"363","author":"Butrynski","year":"2010","journal-title":"N Engl J Med."},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1746-1596-8-147","article-title":"Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review","volume":"8","author":"Li","year":"2013","journal-title":"Diagn Pathol."},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jjco\/hyu069","article-title":"A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib","volume":"44","author":"Kimbara","year":"2014","journal-title":"Jpn J Clin Oncol."},{"key":"R16-20250616","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/leu.2010.18","article-title":"ALK fusion genes in children with atypical myeloproliferative leukemia","volume":"24","author":"R\u00f6ttgers","year":"2010","journal-title":"Leukemia"},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12185-013-1482-x","article-title":"Inv (2)(p23q13)\/RAN-binding protein 2 (RANBP2)\u2013ALK fusion gene in myeloid leukemia that developed in an elderly woman","volume":"99","author":"Maesako","year":"2014","journal-title":"Int J Hematol."},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cancergen.2013.12.003","article-title":"RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia","volume":"207","author":"Lim","year":"2014","journal-title":"Cancer Genet."},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hon.2125","article-title":"Identification of RANBP2\u2013ALK fusion in ALK positive diffuse large B\u2010cell lymphoma","volume":"32","author":"Lee","year":"2014","journal-title":"Hematol Oncol."},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/path.4836","article-title":"ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1\u2010ALK fusions in epithelioid inflammatory myofibroblastic sarcoma","volume":"241","author":"Lee","year":"2017","journal-title":"J Pathol."},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13023-017-0647-8","article-title":"Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma","volume":"12","author":"Jiang","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11748-013-0204-x","article-title":"Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity","volume":"62","author":"Kozu","year":"2014","journal-title":"Gen Thorac Cardiovasc Surg."},{"key":"R23-20250616","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13000-015-0358-1","article-title":"Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature","volume":"10","author":"Fu","year":"2015","journal-title":"Diagn Pathol."},{"key":"R24-20250616","first-page":"E513","article-title":"Epithelioid inflammatory myofibroblastic sarcoma: a case report","volume":"7","author":"Sarmiento","year":"2015","journal-title":"J Thorac Dis."},{"key":"R25-20250616","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1684\/ejd.2017.3213","article-title":"Cutaneous inflammatory myofibroblastic tumour: a case report and literature review","volume":"27","author":"Nakazato","year":"2017","journal-title":"Eur J Dermatol."},{"key":"R26-20250616","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13000-016-0517-z","article-title":"Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature","volume":"11","author":"Yu","year":"2016","journal-title":"Diagn Pathol."},{"key":"R27-20250616","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1600-0560.2011.01747.x","article-title":"EMA positivity in epithelioid fibrous histiocytoma: a potential diagnostic pitfall","volume":"38","author":"Doyle","year":"2011","journal-title":"J Cutan Pathol."},{"key":"R28-20250616","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1600-0560.2012.01944.x","article-title":"Desmin and CD34 positivity in cellular fibrous histiocytoma: an immunohistochemical analysis of 100 cases","volume":"39","author":"Volpicelli","year":"2012","journal-title":"J Cutan Pathol."},{"key":"R29-20250616","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/DAD.0000000000001666","article-title":"Epithelioid fibrous histiocytoma with dot-like perinuclear ALK expression and prkar2a-ALK fusion","volume":"42","author":"Dawson","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"R30-20250616","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1092-9134(02)00022-9","article-title":"Myxoinflammatory fibroblastic sarcoma: a tumor not restricted to acral sites","volume":"6","author":"Jurcic","year":"2002","journal-title":"Ann Diagn Pathol."},{"key":"R31-20250616","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/PAS.0b013e3181ff0901","article-title":"Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior","volume":"35","author":"Hornick","year":"2011","journal-title":"Am J Surg Pathol."},{"key":"R32-20250616","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamadermatol.2013.3190","article-title":"Cutaneous epithelioid sarcomalike (pseudomyogenic) hemangioendothelioma: a little-known low-grade cutaneous vascular neoplasm","volume":"149","author":"Requena","year":"2013","journal-title":"JAMA Dermatol."},{"key":"R33-20250616","first-page":"201","article-title":"Epithelioid inflammatory myofibroblastic sarcoma of small bowel mesentery: report of a case [in Chinese]","volume":"46","author":"Fang","year":"2017","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"R34-20250616","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2169\/internalmedicine.53.2546","article-title":"Epithelioid inflammatory myofibroblastic sarcoma responsive to surgery and an ALK inhibitor in a patient with panhypopituitarism","volume":"53","author":"Kurihara-Hosokawa","year":"2014","journal-title":"Int Med."},{"key":"R35-20250616","first-page":"15328","article-title":"Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Pathol."},{"key":"R36-20250616","doi-asserted-by":"crossref","first-page":"e26920","DOI":"10.1002\/pbc.26920","article-title":"Crizotinib in ALK+ inflammatory myofibroblastic tumors\u2014current experience and future perspectives","volume":"65","author":"Theilen","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R37-20250616","first-page":"2370","article-title":"ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: a case report","volume":"17","author":"Xu","year":"2019","journal-title":"Oncol Lett."},{"key":"R38-20250616","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41416-020-0996-2","article-title":"CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma","volume":"123","author":"Fordham","year":"2020","journal-title":"Br J Cancer"},{"key":"R39-20250616","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jso.23927","article-title":"Prognostic factors and follow\u2010up strategy for superficial soft\u2010tissue sarcomas: analysis of 622 surgically treated patients from the scandinavian sarcoma group register","volume":"111","author":"Tsagozis","year":"2015","journal-title":"J Surg Oncol (Tallinn)"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:01:44Z","timestamp":1750100504000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002096","relation":{},"ISSN":["0193-1091"],"issn-type":[{"type":"print","value":"0193-1091"}],"subject":[],"published":{"date-parts":[[2021,11,23]]}}}